Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,494 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Patch 2 Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

NCT05096494
View directory record Official record
Conditions
Moderate to Severe Acute Lower Back Pain
Interventions
SP-103, Placebo
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Phoenix, Arizona • Fernandina Beach, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Silk Scaffold Surgical Incision Dressing

NCT05508945
View directory record Official record
Conditions
Surgical Incision
Interventions
Dermabond Prineo Skin Closure System, silk, 3M Steri-Strip
Device
Lead sponsor
Mehrdad Mark Mofid
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Performance Output With Haptics - Evaluating Athlete Response and Unrealized Potential

NCT06430879
View directory record Official record
Conditions
Muscle Strength, Muscle Weakness
Interventions
VICTORY PATCH, Sham Patch without VTT
Device
Lead sponsor
SuperPatch Limited LLC
Industry
Eligibility
18 Years to 30 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use

NCT00218296
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Usual Care Group, Reduction Group
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Phase 1Phase 2 Interventional

Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx

NCT00064103
View directory record Official record
Conditions
Lip and Oral Cavity Cancer, Oropharyngeal Cancer, Stage 0 Lip and Oral Cavity Cancer, Stage 0 Oropharyngeal Cancer, Tongue Cancer
Interventions
Ad5CMV-p53 gene, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 20, 2026, 2:11 PM EDT
Completed No phase listed Observational

A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer

NCT04951154
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Bronchoscopic Biopsy, Blood Sample
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 20, 2026, 2:11 PM EDT
Completed No phase listed Observational

Multi-site Near Infrared Spectroscopy (NIRS) Monitoring of Children During Exercise

NCT00556231
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
6 Years to 20 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

NCT06257537
View directory record Official record
Conditions
Osteo Arthritis Knee, Arthritis
Interventions
Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac Patches, SAM Patch
Device · Drug · Other
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Stamford, Connecticut • Trumbull, Connecticut • Dryden, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Phase 3 Interventional

Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain

NCT01968005
View directory record Official record
Conditions
Low Back Pain
Interventions
Etoreat®(Etodolac-Lidocaine Topical Patch), Placebo
Drug
Lead sponsor
MEDRx USA, Inc.
Industry
Eligibility
14 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Carlsbad, California • Miami, Florida • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 20, 2026, 2:11 PM EDT
Active, not recruiting Not applicable Interventional

A Phase II Study of Pre-Op SRS Followed by Surgical Resection for Brain Metastases

NCT05341739
View directory record Official record
Conditions
Brain Metastases, Adult
Interventions
Pre-operative Stereotactic Radiosurgery
Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

CAN-DOSE Study: Cessation With Augmented Nicotine for Dual Use Of Smoking and E-cigarettes

NCT06087328
View directory record Official record
Conditions
Smoking Cessation, Electronic Cigarette Use, Cigarette Smoking
Interventions
Regular Nicotine patch and lozenge dose, Augmented Nicotine patch and lozenge dose
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Varenicline and Combined NRT for Smoking Cessation

NCT02271919
View directory record Official record
Conditions
Cigarette Smoker, Tobacco Use Disorder
Interventions
Nicotine Lozenge, Nicotine Patch, Placebo, Tobacco Cessation Counseling, Varenicline
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
631 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 20, 2026, 2:11 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

NCT03295981
View directory record Official record
Conditions
Giant Cell Tumor of Bone
Interventions
Zoledronic Acid
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
14
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 2:11 PM EDT
Active, not recruiting Not applicable Interventional

CREST: Capsular Repair During Hip Arthroscopy

NCT03372564
View directory record Official record
Conditions
Hip Arthroscopy
Interventions
Hip Capsule Repair
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2040
U.S. locations
3
States / cities
Scottsdale, Arizona • Westmont, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Phase 4 Interventional Results available

Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE

NCT04569799
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Lumason
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neurobiology of Nicotine and Non-nicotine Components of Tobacco Addiction

NCT01056926
View directory record Official record
Conditions
Smoking
Interventions
Quit smoking, Nicotine patch, Placebo Patch
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Body Temperature in Persons With Tetraplegia When Exposed to Cold

NCT01822535
View directory record Official record
Conditions
Tetraplegia, Hypothermia, Mild Cognitive Impairment
Interventions
Midodrine hydrochloride
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 68 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 20, 2026, 2:11 PM EDT
Not listed Phase 1 Interventional

Nicotine Treatment of Mild Cognitive Impairment (MCI)

NCT00091468
View directory record Official record
Conditions
Age-Related Memory Disorders
Interventions
Transdermal nicotine patch, Placebo transdermal patch
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Durham, North Carolina • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 20, 2026, 2:11 PM EDT
Enrolling by invitation No phase listed Observational

Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body Wash

NCT06665490
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma
Interventions
CLn Body Wash
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Phase 2 Interventional

Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia

NCT00478179
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
Transdermal/Patch (Bupivacaine TTS [Eladur™])
Drug
Lead sponsor
Durect
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
La Jolla, California • Loma Linda, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2009 · Synced Oct 20, 2026, 2:11 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers

NCT01892813
View directory record Official record
Conditions
Nicotine Dependence, Tobacco Use
Interventions
Nicotine replacement therapy - Transdermal nicotine patch, Nicotine replacement therapy - Nicotine gum, Nicotine replacement therapy - Nicotine lozenge, Bupropion, Varenicline, Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum, Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge, Combination pharmacotherapy - Transdermal nicotine patch + bupropion, Tobacco quitline referral, Tailored behavioral intervention, Alcohol use risk reduction, Behavioral activation for depressive symptoms, Behavioral management of postcessation weight gain
Drug · Behavioral
Lead sponsor
Mark Vander Weg
Other
Eligibility
18 Years to 99 Years
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Not applicable Interventional

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

NCT04694846
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Phase 2 Interventional

Intra-oral Treatment of OLP With Rivelin®-CLO Patches

NCT03592342
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
Clobetasol Propionate
Drug
Lead sponsor
Dermtreat
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Hialeah, Florida • Miami, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 20, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

NCT03603808
View directory record Official record
Conditions
Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
Interventions
Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
Device · Biological · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 20, 2026, 2:11 PM EDT